Axsome Therapeutics, Inc. (AXSM) intrinsic value & 10-year financials
Axsome Therapeutics, Inc. (AXSM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 71.3% a year to $638.5M, with an average return on invested capital of 1247.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $157.14
- Market cap
- $7.8B
- Revenue (FY2025)
- $638.5M
- Revenue growth (10-yr CAGR)
- 71.3%
- ROIC (10-yr avg)
- 1247.3%
- Free cash flow (FY2025)
- -$93.9M
AXSM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $638.5M | -$183.2M | -$3.68 | -$93.9M | -26.1% | 377.3% |
| FY2024 | $385.7M | -$287.2M | -$5.99 | -$128.7M | -72.7% | 712.5% |
| FY2023 | $270.6M | -$239.2M | -$5.27 | -$145.7M | -85.7% | 6495.8% |
| FY2022 | $50.0M | -$187.1M | -$4.60 | -$117.2M | -359.3% | 1914.8% |
| FY2021 | $74.1M | -$130.4M | -$3.47 | -$108.5M | -168.4% | 580.9% |
| FY2020 | — | -$102.9M | -$2.77 | -$78.5M | — | 466.7% |
| FY2019 | — | -$68.3M | — | -$46.4M | — | 490.3% |
| FY2018 | — | -$31.0M | — | -$30.1M | — | 486.9% |
| FY2017 | — | -$28.9M | — | -$26.5M | — | 428.5% |
| FY2016 | — | -$27.2M | — | -$21.4M | — | 519.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Axsome Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Axsome Therapeutics, Inc. returns on capital have been average, hovering around 12.5% ROIC over the decade.
Axsome Therapeutics, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Axsome Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-122.23 per share.